These results emphasize the clinical relevance of activating AMPK in the liver to combat NAFLD and potentially other associated complications (e.g., cirrhosis and hepatocellular carcinoma). Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.